Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: The story doesn’t address costs for any of the treatment options discussed. Is MBSR comparable to CBT? Does insurance cover either treatment option? The story tells readers what percentage of study participants who got MBSR treatment reported improvement in pain, as well as what percentage of MBSR participants “reported improvement in the activities they could do.” It also offered the same numbers for participants who received CBT and for the control group, which received typical medical care for this condition. These details deserve a Satisfactory rating. But: The story notes: “The study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an ‘adverse event,’ most often an increase in pain due to yoga.” It’s good to see that included. Since the story is effectively comparing MBSR to CBT and conventional treatment, it would also have been worth noting “adverse events” for those groups in the study. According to the study, 10 percent of the CBT group also experienced “adverse events,” and no adverse events were mentioned for the control group. Defining “adverse events” would also have been good, since it’s not clear whether they mean momentary pain or a debilitating flare-up of long-term pain. According to the study, the pain–for both MBSR and CBT groups–was “mostly temporary” and no “serious” adverse events were reported. Those things are worth mentioning. (It’s also worth finding out what “mostly” and “serious” mean.) The story describes the study in detail, explicitly stating the study size and the absolute percentages in each arm that had benefit. It also acknowledged the study was randomized. We’ll count this as sufficient for Satisfactory, keeping in mind the following: As explained in the summary above, the story doesn’t make clear MBSR and CBT were used in addition to conventional medical treatment, rather than instead of medical treatment. The story didn’t mention that the study excluded participants with what the study authors term “a specific diagnosis (eg, spinal stenosis).” In other words, the study did not address treatments for back pain caused by issues like a herniated disc or rheumatoid arthritis. Many readers have these conditions, and should be informed that these study results may not be applicable to their situation. Lastly, we would have welcomed a discussion of the high rates of success within the control group. Forty-four percent in that group experienced a gain in functionality, for example. That seems pretty good! What do the researchers have to say about that? No disease mongering here. However, we did want to point out that the story “fear mongers” in a sense, by stating back pain is “one reason why more and more people are addicted to painkillers.” The story insinuates that these other treatment methods–especially meditation–could help with that. And maybe they could. But the study itself says “No overall differences in treatment effects were observed for…self-reported use of medications for back pain.” So why the mention of painkiller addiction? Conflicts of interest don’t appear to be an issue here, and the story includes statements from an accompanying editorial in JAMA, which was written by experts unaffiliated with the research. This squeaks by as Satisfactory, though it should be noted that most of this material was available via news releases (see below). The story is effectively all about comparing alternatives, though–again–it should have made clear that MBSR and CBT were used in conjunction with conventional medical treatment, and it left out discussion of other well-known non-medication treatment methods, such as exercise. It’s not clear from the story whether MBSR is widely available, is available in mainly metropolitan areas, or is a relatively new field that is still uncommon. The story does quote from a separate editorial in JAMA that says health care systems “should provide access to affordable mind-body therapies,” implying that it’s not widely available. Is this the case, or can it be easily accessed? Given the constraints of a brief news story, the piece does a nice job of articulating the differences between MBSR and CBT. It would have been even more helpful for the story to mention previous studies on the impact of MBSR and CBT on low back pain, to help us understand how novel this new study is. There is little in the story that is not found in the two news releases issued on this study. (Those releases can be found here and here.)
Example Output: Mindful meditation may be the answer to relieving chronic back pain, study suggests

Example Input: U.S. scientists said the infection in a 49-year-old Pennsylvania woman “heralds the emergence of truly pan-drug resistant bacteria” because it could not be controlled even by colistin, an antibiotic reserved for “nightmare” bugs. In Japan, British Prime Minister David Cameron said leading countries needed to tackle resistance by reducing the use of antibiotics and rewarding drug companies for developing new medicines. “In too many cases antibiotics have stopped working. That means people are dying of simple infections or conditions like TB (tuberculosis), tetanus, sepsis, infections that should not mean a death sentence,” he told a news conference at a summit in Japan. “If we do nothing about this there will be a cumulative hit to the world economy of $100 trillion and it is potentially the end of modern medicine as we know it.”  A review commissioned by the British government and published last week said a reward of between $1 billion and $1.5 billion should be paid for any successful new antimicrobial medicine brought to market. If the problem is not brought under control, antimicrobial resistance could kill an extra 10 million people a year by 2050, the review warned. The U.S. case is a further wake-up call for the world, although it is not the first time that colistin resistance has appeared. Medics around were alarmed last year by the discovery in China of a new gene that makes bacteria highly resistant to the medicine. Since then, the deadly strain has also been detected in Europe and Canada. The development of colistin resistance is linked to the drug’s widespread use in livestock and the European Medicines Agency on Thursday called for a 65 percent cut in the amount of the medicine used in farming. “The more we look at drug resistance, the more concerned we are,” Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention, told reporters in Washington. “The medicine cabinet is empty for some patients. It is the end of the road for antibiotics unless we act urgently.”  The problem is aggravated by drugmakers’ reluctance to invest in developing new antibiotics, preferring to focus on more profitable disease areas, although recently there has been some increase in investment, prompted by the superbug threat. In January, 83 companies, including Pfizer (PFE.N), Merck & Co (MRK.N), Johnson & Johnson (JNJ.N) and GlaxoSmithKline (GSK.L), signed a declaration urging governments to support work on new antibiotics.
Example Output: G7 told to act on antibiotics as dreaded superbug hits U.S.

Example Input: The article does not offer any cost information. The article offers general statements about the “dramatic” and rapid effects of UA from Allergan researchers, but does not provide any numerical context or offer summaries of research with that information. The article notes the side effects of UA and potentially two other similar drugs in the pipeline. The main concern about these agents is the effects they may have on the endometrium (uterine lining) over time. The evidence is generally AWOL. A personal testimonial from a celebrity with fibroids does not stand in for evidence one expects to see from a clinical trial or trials. No mongering here. The article quotes one outside expert whose comments focused on the use of an injectable alternative to the oral drug, and the downsides of this alternative. But it also has a comment from Allergan’s researcher noting that longer-time follow up is needed for UA. These source’s commercial relationships are appropriately disclosed. [Editor’s note: Following publication of this review, we learned that Allergan provides financial support to the White Dress Project. The story would have done well to acknowledge this relationship.] The article mentions some alternative treatments in detail. One strength of the article is that it prominently points out that many women with fibroids who have no symptoms do not require treatment of any kind. The article notes the new drug could be available in the US next year. The drug is already available in the US for another indication but is packaged in doses that are much larger than those used for fibroid treatments. The article makes clear that the advantage of the new drug is that it is an oral medication, and is taken for a limited time. However, ulipristal is not the first oral medication. There are some older oral hormonal medications, including pills in some cases, that have been tried. GnRH agonists (delivered by injection or nasal spray) such as Lupron have been used in limited situations to treat fibroids, but their use is limited by side effects related to medically induced menopause. The story includes comments from two experts and it appears as though the second one had no involvement with the study.
Example Output:
New Treatment for Fibroids Without Surgery